RECRUITING

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Talk to us

Conditions

Spinal and Bulbar Muscular AtrophyKennedys DiseaseMotor Neuron DiseaseAndrogen ReceptorNatural History StudyNatural History

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors. Researchers want to learn more about the effects of SBMA. Objective: To identify measurements that change over time in SBMA, including tests of muscle strength and function, as well as measurements of muscle and fat size. Eligibility: Men over the age of 18 both with and without a history of SBMA. Design: Participants will have a medical history, physical exam, and blood and urine tests. They will have neuromuscular ultrasound. They will have a lumbar puncture to obtain spinal fluid. For this, a needle will be inserted into the spinal canal in the lower back. Participants will have muscle strength and function tests. These tests may include pushing, pulling, rising from a chair and sitting back down, and/or walking. During these tests, they may wear an accelerometer (activity tracker) on their wrist. Participants will get an activity tracker to wear on their wrist for 10 days at home every 3 months. Participants with SBMA will also have lower limb magnetic resonance imaging (MRI) and optional whole-body MRI. They will have lung function tests. They will have speech and swallow tests. They will complete questionnaires. They may have optional body scans to measure bone density and lean body mass. They may have optional muscle biopsies. For biopsies, a needle will be used to take a small piece of muscle from the leg. Participants with SBMA will have 5 study visits over 2 years (every 6 months). Participants without SBMA will have 1 study visit.

Official Title

An Observational Study to Assess Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Quick Facts

Study Start:2021-10-25
Study Completion:2027-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04944940

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 120 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Stated willingness to comply with all study procedures and availability for the duration of the study
  2. * Male, above the age of 18 years
  3. * Genetically confirmed SBMA
  4. * Ability of subject to understand and the willingness to sign a written informed consent document
  5. * Ability of subject to travel to the NIH Clinical Center.
  6. * Spinal bulbar muscular atrophy functional rating of \< 50 (and \> 35).
  7. * On initial whole body MRI, subject has evidence of muscle fat replacement such that the total volume of disease affected muscles (i.e., muscles with at least 10% muscle fat infiltration and no more than 50% muscle fat fraction) is at least:
  8. * 500ml if only 1 muscle is eligible or
  9. * 250ml if more than one muscle meets the criteria
  10. * Stated willingness to comply with all study procedures and availability to travel to the NIH for the duration of the study
  11. * Male, above the age of 18 years
  12. * No history of SBMA or other neuromuscular disorder
  13. * No history of facial palsy
  14. * Ability of subject to understand and the willingness to sign a written informed consent document
  15. * Ability of subject to travel to the NIH Clinical Center.
  1. * Contraindications to MRI such as a contraindicated non-removable metal device (i.e., pacemaker, defibrillator, insulin pump, metal clips, non-removable jewelry) or claustrophobia.
  2. * Non ambulatory
  3. * PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  4. * INR greater than or equal to 1.5, thrombocytopenia (\<70,000), or abnormal bleeding time or platelet dysfunction
  5. * History of a bleeding disorder
  6. * Use of anticoagulants
  7. * Use of androgen reducing agents within the past two years
  8. * PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  9. * INR greater than or equal to 1.5, thrombocytopenia (less than 70,000), or abnormal bleeding time or platelet dysfunction
  10. * History of a bleeding disorder
  11. * Use of anticoagulants
  12. * Advanced wasting of tibialis anterior that precludes needle muscle biopsy (in order to ensure that a sample taken would be of muscle and not just fat and fascia)
  13. * Use of aspirin or non-steroidal anti-inflammatory agents 3 days prior to the procedure
  14. * Patient has a history of prior treatment with androgen reducing agents including LHRH agonists or antagonists, androgen receptor antagonists and selective androgen receptor modifiers.
  15. * Patient is unable to complete the study assessments of QMT or timed walk tests.
  16. * Patient anticipates making major lifestyle changes during the observation period relating to diet and exercise.
  17. * PT/PTT values that are prolonged greater than or equal to 3 seconds from the upper limit of normal (including treatment with oral and parenteral anticoagulants)
  18. * INR greater than or equal to 1.5, thrombocytopenia (less than 70,000), or abnormal bleeding time or platelet dysfunction
  19. * History of a bleeding disorder
  20. * Use of anticoagulants

Contacts and Locations

Study Contact

Angela Kokkinis, R.N.
CONTACT
(301) 451-8146
akokkinis@mail.cc.nih.gov
Christopher Grunseich, M.D.
CONTACT
(301) 402-5423
grunseichc@mail.nih.gov

Principal Investigator

Christopher Grunseich, M.D.
PRINCIPAL_INVESTIGATOR
National Institute of Neurological Disorders and Stroke (NINDS)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

  • Christopher Grunseich, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Neurological Disorders and Stroke (NINDS)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-10-25
Study Completion Date2027-02-28

Study Record Updates

Study Start Date2021-10-25
Study Completion Date2027-02-28

Terms related to this study

Keywords Provided by Researchers

  • Motor Neuron Disease
  • Spinal and Bulbar Muscular Atrophy
  • Kennedys disease
  • Androgen Receptor
  • Natural History Study
  • Natural History

Additional Relevant MeSH Terms

  • Spinal and Bulbar Muscular Atrophy
  • Kennedys Disease
  • Motor Neuron Disease